Last reviewed · How we verify
Chronic heart failure
Approved treatments
- Diovan · Bayer
- Spironolacton · ACS Biomarker
- Dapaglifozin · MedImmune LLC
- Diuril · Salix Pharms
- Verquvo · Merck & Co.
Verquvo works by stimulating the enzyme guanylate cyclase to increase levels of a molecule called cGMP, which helps to relax blood vessels and improve heart function. - Jardiance · Boehringer Ingelheim
SYNJARDY combines empagliflozin, which inhibits SGLT2 to increase urinary glucose excretion, and metformin HCl, which improves glucose tolerance and insulin sensitivity. - Capozide 25/15 · Aarxion Anda Hlding
- Accupril · Pfizer
- Atacand · ANI Pharmaceuticals
Atacand blocks the action of angiotensin II, a hormone that constricts blood vessels, to lower blood pressure and improve heart function. - Corlanor · Amgen
- Lopressor · Generic (originally Ciba-Geigy/Novartis)
Cardioselective beta-1 adrenergic receptor blocker that reduces heart rate, blood pressure, and myocardial oxygen demand. - Zestril · Generic (originally Merck/AstraZeneca)
Inhibits angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, lowering blood pressure and reducing cardiac workload. - Diovan · Novartis
Diovan works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure. - Microzide · Generic (originally Merck)
Lisinopril inhibits ACE, reducing angiotensin II and aldosterone, leading to lower blood pressure. - Aldactone · Generic (originally Searle/Pfizer)
Potassium-sparing diuretic and mineralocorticoid receptor antagonist that blocks aldosterone, reducing fluid retention and lowering blood pressure. - DAPA · Astrazeneca Ab
- Persantin · Boehringer Ingelheim
- Farxiga · AstraZeneca
Farxiga works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine. - Coreg · Waylis
Coreg works by blocking the effects of the hormone epinephrine on the heart, reducing its workload and improving its function. - Monopril
Monopril works by blocking the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. - Persantine · Boehringer Ingelheim
Persantine works by inhibiting platelet activation and aggregation by blocking the equilibrative nucleoside transporter 1. - Lanoxin · Generic (originally Burroughs Wellcome/GSK)
- Altace · King Pfizer
Altace works by blocking the action of angiotensin-converting enzyme, a key player in the renin-angiotensin-aldosterone system that regulates blood pressure. - Forxiga · AstraZeneca Turkey
- Jardiance · University of Louisville
- Farxiga · AstraZeneca
- Mavik · Dr. Reddy's Laboratories Limited
- spirolactone · Second Xiangya Hospital of Central South University
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Chronic heart failure patent landscape — cliff calendar, originator estates, attackable patents
- Chronic heart failure treatment landscape brief
- Chronic heart failure treatment updates RSS
Frequently asked questions about Chronic heart failure
What drugs treat Chronic heart failure?
Tracked treatments include Diovan, Spironolacton, Dapaglifozin, Diuril, Verquvo, Jardiance, Capozide 25/15, Accupril.
What is the treatment for Chronic heart failure?
Standard treatment for Chronic heart failure includes Diovan, Spironolacton, Dapaglifozin, Diuril, Verquvo. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Chronic heart failure patent cliff · Chronic heart failure CI report
- Treatment: Diovan · Bayer
- Treatment: Spironolacton · ACS Biomarker
- Treatment: Dapaglifozin · MedImmune LLC
- Treatment: Diuril · Salix Pharms
- Treatment: Verquvo · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing